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NADH-Cytochrome b5 Reductase 3 Promotes
Colonization and Metastasis Formation and Is
a Prognostic Marker of Disease-Free and
Overall Survival in Estrogen Receptor-Negative
Breast Cancer*□S
Rikke R. Lund‡ ‡‡, Rikke Leth-Larsen‡, Tina Di Caterino§, Mikkel G. Terp‡,
Jeanette Nissen‡, Anne-Vibeke Lænkholm¶, Ole N. Jensen, and Henrik J. Ditzel‡**§§
Metastasis is the main cause of cancer-related deaths
and remains the most significant challenge to manage-
ment of the disease. Metastases are established through
a complex multistep process involving intracellular signal-
ing pathways. To gain insight to proteins central to spe-
cific steps in metastasis formation, we used a metastasis
cell line model that allows investigation of extravasation
and colonization of circulating cancer cells to lungs in
mice. Using stable isotopic labeling by amino acids in cell
culture and subcellular fractionation, the nuclear, cytosol,
and mitochondria proteomes were analyzed by LC-MS/
MS, identifying a number of proteins that exhibited altered
expression in isogenic metastatic versus nonmetastatic
cancer cell lines, including NADH-cytochrome b5 reduc-
tase 3 (CYB5R3), L-lactate dehydrogenase A (LDHA), Ni-
emann-pick c1 protein (NPC1), and nucleolar RNA heli-
case 2 (NRH2). The altered expression levels were
validated at the protein and transcriptional levels, and
analysis of breast cancer biopsies from two cohorts of
patients demonstrated a significant correlation between
high CYB5R3 expression and poor disease-free and over-
all survival in patients with estrogen receptor-negative
tumors (DFS: p  .02, OS: p  .04). CYB5R3 gene knock-
down using siRNA in metastasizing cells led to signifi-
cantly decreased tumor burden in lungs when injected
intravenously in immunodeficient mice. The cellular ef-
fects of CYB5R3 knock-down showed signaling altera-
tions associated with extravasation, TGF and HIF
pathways, and apoptosis. The decreased apoptosis of
CYB5R3 knock-down metastatic cancer cell lines was
confirmed in functional assays. Our study reveals a cen-
tral role of CYB5R3 in extravasation/colonization of can-
cer cells and demonstrates the ability of our quantitative,
comparative proteomic approach to identify key proteins
of specific important biological processes that may also
prove useful as potential biomarkers of clinical relevance.
MS data are available via ProteomeXchange with identi-
fier PXD001391. Molecular & Cellular Proteomics 14:
10.1074/mcp.M115.050385, 2988–2999, 2015.
The development of metastasis is a complex, multistep
process that includes activation of an aberrant intracellular
signaling pathway responsible for signal transduction that
enables cancer cells to interact with the environment, prolif-
erate, avoid apoptosis, and thus colonize in the new environ-
ment (1). It has been proposed that the final steps in the
metastatic process, metastatic colonization, referring to out-
growth of cancer cells at a distant site, may hold the most
therapeutic promise (2). It was further suggested that thera-
pies that interrupt metastatic colonization might be most ben-
eficial to patients at high risk of developing metastasis (2).
Several key molecules involved in different intracellular sig-
naling pathways important for cancer and metastasis forma-
tion have been characterized. Among these are p53, which,
when mutated, is able to regulate proteins that mediate cen-
tral steps in metastasis, such as proliferation, drug resistance,
and survival (3). The p53 protein has been found to have very
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diverse roles in cancer cells: in the nuclei as transcription
factor guarding the cell in response to various stress signals
and in the cytoplasm modulating miRNA processing and sur-
vival proteins in the mitochondria (4). Other intracellular pro-
teins associated with metastasis include the actin cytoskele-
ton-regulating proteins, e.g. the rho family of small GTPases,
which play a crucial role in cell motility (5, 6), and proteins
downstream of the human epidermal growth factor receptor,
e.g. the ras/raf/mitogen-activated protein kinase pathway in-
volved in cell migration and proliferation and phosphatidylino-
sitol 3-kinase/akt pathway regulating cell growth, apoptosis,
invasion, and migration (7).
Analysis of the individual steps of the metastatic process is
not possible using patient tissue or in vitro assays, but in vivo
models based on inoculation of isogenic human cell lines with
different phenotypes into mice may allow studies of these
processes and provide the means for comparative molecular
screening and functional evaluation of candidate metastasis-
related genes and proteins. One such metastasis model is
based on the isogenic cell lines, NM-2C5 and M-4A4, which
are equally tumorigenic in immunodeficient mice but only the
latter produces metastases in the lungs and lymph nodes.
Although NM-2C5-derived primary tumors disseminate single
cells to the lungs, they remain dormant and do not form
metastases (8, 9). Hence, the model recapitulates the mech-
anistic steps of extravasation and colonization of circulating
cancer cells at distant sites, while avoiding problems inherent
with the variations in genetic backgrounds of human tissue
samples. Additionally, this model overcomes the complexities
of identifying cells with metastatic potential from primary tu-
mors (8, 9). Gene expression (10–12), miRNA expression (13),
and analysis of plasma membrane proteins (14–16), ribo-
somal proteins (17), secreted proteins (18), soluble proteins
(19), and phosphoproteins (20) from these cell lines has been
described. In previous studies of this model, we analyzed the
plasma membrane proteome and found higher expression of
CD73 (ecto-5-nucleotidase) and integrin 1 in M-4A4 versus
NM-2C5, which was correlated with poor outcome of breast
cancer patients (15).
Here, we describe a quantitative, comparative LC-MS/MS
analysis of intracellular proteins from the cytosol, mitochon-
dria, and nuclei by analyzing four subfractions of proteins
metabolically labeled with amino acids containing stable iso-
topes from the NM-2C5 and M-4A4 cells. Among the proteins
exhibiting altered expression between the two cell lines,
NADH-cytochrome b5 reductase 3 (CYB5R3)1, L-lactate de-
hydrogenase A (LDHA), Niemann-pick c1 protein (NPC1), and
nucleolar RNA helicase 2 (NRH2) were further studied using
other biochemical techniques and their expression analyzed
in primary breast cancer tissue biopsies of two cohorts of
patients. The expression of CYB5R3, a membrane-bound
enzyme not identified in any of the previous studies, was
shown to correlate with clinical outcome, and its effect on
extravasation and colonization was evaluated by injecting
M-4A4 cells transfected with CYB5R3 siRNA or control siRNA
into the tail vein of immunodeficient mice, demonstrating a
reduction of lung metastasis when CYB5R3 expression was
significantly reduced. Our study demonstrates a central role
of CYB5R3 in extravasation/colonization of breast cancer
cells.
EXPERIMENTAL PROCEDURES
Cell Culture and Stable Isotopic Labeling by Amino Acids in Cell
Culture Reagents—The human breast carcinoma cell lines, NM-2C5
and M-4A4, kindly provided by Dr. David Tarin, UCSD Cancer Center,
California, were propagated as previously described (14). For pro-
teome analysis, the medium of the NM-2C5 cell line was supple-
mented with 12C6-L-arginine and
12C6- L-lysine (Sigma-Aldrich, St.
Louis, MO), whereas that of the M-4A4 cell line was supplemented
with 13C6-L-arginine and
13C6-L-lysine (Cambridge Isotope Laborato-
ries, Andover, MA). To ensure complete incorporation of the stable
isotopes, the cells were grown to at least five cell doublings in the
customized media before isolating the proteins. The incorporation of
stable isotopes was monitored by MS, as described previously (14).
Proteome analysis was performed on cultures passaged no more
than ten times from frozen stock vials designated passage 1 at the
time of in vivo inoculation, thereby insuring genetic stability.
Subcellular Fractionation—All steps were performed at 4 °C or on
ice, and all buffers contained Complete Protease Inhibitor (Roche
Diagnostics, Mannheim, Germany). Cells were rinsed in PBS, re-
moved from the flasks using a cell scraper, and the two cell lines were
counted and mixed in a 1:1 ratio (a total of 2–8  107cells), followed
by two rounds of washing in PBS. Cells were lysed by incubation in a
hypotonic buffer (10 mM Tris-base, 1.5 mM MgCl2, and 10 mM NaCl,
pH 6.8) for 5 min followed by sedimentation by centrifugation (300 
g, 5 min), resuspended in gradient buffer (0.25 M Sucrose, 10 mM
HEPES, 100 mM succinic acid, 1 mM EDTA, 2 mM CaCl2, and 2 mM
MgCl2, pH 7.4) and homogenized by 50 strokes (1,500 rev/min) using
a motor-driven Potter homogenizer (B. Braun Biotech, Allentown, PA).
The homogenate was centrifuged at 1,000  g for 10 min.
A preparation of the nuclear proteins was isolated from the sedi-
mented homogenate. The pellet was resuspended in 0.5 ml 0.25 M
sucrose, 10 mM MgCl2, 20 mM Tris-HCl (pH 7.4), and 1 mM DTT and
layered on top of a two-step discontinuous sucrose gradient (1.3 M
sucrose in 6.25 mM MgCl2, 20 mM Tris-HCl (pH 7.4), 0.5 mM DTT, and
2.3 M sucrose in 2.5 mM MgCl2, 20 mM Tris-HCl (pH 7.4)). Nuclei and
cell debris were separated by centrifugation (5,000 g, 45 min, 4 °C),
and two layers of protein material were isolated (both layers were
analyzed by LC-MS/MS). These layers were carefully resuspended in
1 ml 10 mM HEPES (pH 7.9), 10 mM KCl, 1.5 mM MgCl2, and 1 mM
DTT, and the nuclei were sedimented by centrifugation (1,000  g, 5
min, 4 °C). The supernatants were discarded, and the pellets resus-
pended in 1 ml gradient buffer. The nuclei were sonicated (2 min at
10% power) to release the proteins, which were centrifuged at
1,000  g for 15 min at 4 °C and the supernatants recovered. A
preparation of the cytosolic proteins was isolated using the post-
nuclear supernatant from the sedimented homogenate by recovering
the supernatant after further sedimenting the membrane proteins by
centrifugation at 120,000  g for 60 min in a M150GX microultracen-
1 The abbreviations used are: CYB5R3, NADH-cytochrome b5 re-
ductase 3; DFS, disease-free survival; ER, estrogen receptor; HER2,
receptor tyrosine-protein kinase erbB-2; LDHA, L-lactate dehydro-
genase A; MAPK, mitogen-activated protein kinase; MMP, matrix
metallopeptidase; Neg, negative; NPC1, Niemann-pick c1 protein;
NRH2, nucleolar RNA helicase 2; OS, overall survival; Pos, positive;
PR, progesterone receptor.
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trifuge (Sorvall, Asheville, NC) using a S55-S swing-out rotor (Sorvall).
Nuclear and cytosolic proteins were isolated from the same batch of
cells and in three biological replicates. Mitochondrial proteins were
isolated using Percoll/sucrose density membrane separation as de-
scribed in reference (14), but rather than using the top fractions
containing the plasma membrane proteins, the lower fractions con-
taining the mitochondrial proteins were identified by enzymatic as-
says and isolated. Briefly, the homogenate was centrifuged as de-
scribed above and the recovered supernatant was ultracentrifuged
(100,000  g, 30 min). The pellet, containing crude membranes, was
resuspended in gradient buffer and sedimented twice (100,000  g,
30 min). The purified and washed membranes were resuspended in 2
ml gradient buffer by manual homogenization (five strokes) and mixed
with 1.9 ml Percoll (Amersham Biosciences, Uppsala, Sweden) con-
taining 10% PBS and 0.19 ml 2.5 M sucrose in an Easy-SealTM tube
(polyallomer, 5 ml, Sorvall). The tube was filled with gradient buffer,
capped, and centrifuged at 120,000  g for 15 min. The gradient was
fractionated from the top into ten fractions of 235 l by displacing it
from the bottom with 2 M sucrose. Percoll was removed by centrifu-
gation at 900,000  g for 15 min. The fractions containing the mito-
chondrial proteins were identified by determining the activity of suc-
cinate dehydroxygenase as described previously (14). Mitochondrial
proteins were isolated in three biological replicates. Protein concen-
trations were determined in triplicate using a colorimetric, detergent-
compatible, Lowry-based assay (DC protein assay, Bio-Rad, Hercu-
les, CA) in accordance with the manufacturer’s protocol and using a
BSA preparation as standard (Pierce, Rockford, IL).
Preparation for Mass Spectrometry—Nuclear and mitochondrial
proteins (50 g) were digested as previously detailed (14). Cytosolic
proteins were precipitated in acetone (four volumes, 80 °C, 1 h),
sedimented by centrifugation (10.000  g, 10 min, 4 °C), and the
supernatant carefully removed. The pellet was washed twice with
ice-cold acetone/water (4:1) and dried in a fume hood for 15 min. The
proteins were resolubilized in 50 mM NH4HCO3, 10 mM DTT and
incubated at 56 °C for 30 min, after which iodoacetamide was added
to a final concentration of 40 mM and incubated at room temperature
in the dark for 60 min. The proteins were digested at 37 °C overnight
using trypsin (2 g enzyme/100 g protein), and the peptides were
vacuum-dried to a volume of 20 l and acidified by adding formic
acid. The tryptic peptides were desalted and concentrated on an
Empore C18 extraction disk (3 M, St. Paul, MN) and reverse-phase
POROS R3 (Perseptive Biosystems, Foster City, CA) packed in
GELoader tips (Eppendorf, Hamburg, Germany) using a modified
version of the previously described StageTips (14, 21, 22).
Liquid Chromatography–Tandem Mass Spectrometry—Peptides
from the nuclear and cytosolic preparations were analyzed by nano-
flow LC-MS/MS. Peptide separation was achieved with an LC-Pack-
ings Ultimate 3000 nanoflow system (LC Packings, Amsterdam, The
Netherlands). Peptides were loaded at a flow rate of 3 l/min onto a
custom-made 1 cm precolumn (75 m inner diameter) of fused silica
with kasil-frits retaining the Reprosil C18, 3.5 m reversed-phase
particles (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany).
Nanoflow reversed-phase HPLC was then performed with a flow rate
of 0.2 l/min through a custom-made 8–12 cm analytical column (50
m inner diameter) packed with Reprosil C18-AQ, 3 m reversed-
phase particles (Dr. Maisch, GmbH). Peptides were eluted directly
into the ESI source of a Q-TOF LCT Premier tandem mass spectrom-
eter (Waters/Micromass, Manchester, UK) using a stepped linear
gradient (solvent A: 0.1% CH3COOH, solvent B: 95% acetonitrile,
0.1% CH3COOH): 0% B for 10 min, 0–35% B 90 min, and 35–100%
B for 5 min. Mass- and charge-dependent collision energies were
used for peptide fragmentation. Peptides from the mitochondrial
preparations were separated similarly to the nuclear and cytosolic
proteins but analyzed using a Q-TOF Micro tandem mass spectrom-
eter (Waters/Micromass) as previously described (14). All protein
preparations were analyzed in three technical replicates; one-third of
the 50 g protein used for protein digestion was used for each
triplicate. The mass spectrometry proteomics data have been depos-
ited to the ProteomeXchange Consortium (23) via the PRIDE partner
repository with the dataset identifier PXD001391.
MS/MS Database Search and Quantification—Peak list files were
created using Masslynx 4.0 (Waters/Micromass) with the following
processing parameters: background subtraction: polynomial order
10, 10% below curve; smoothing: Savitzky Golay, three channels, two
smooths; centroiding: min peak with at half height, 4, centroid top,
80%. The data were searched against all human proteins and com-
mon contaminants (n  77,317) in the Mass Spectrometry Interna-
tional Protein Index (MSIPI) database (24) as of April 1, 2009 (ftp://
ftp.ebi.ac.uk/pub/databases/IPI/msipi/) using an in-house Mascot
server v2.2 (Matrix Science Ltd., London, UK). Search parameters
were: 50 ppm precursor ion mass tolerance, 0.2 Da fragment ion
mass tolerance, enzyme-specificity: trypsin (C terminally to R and K
but not RP and KP), one missed cleavage, fixed modifications: cys-
teine carbamidomethyl, variable modifications: oxidation (M), label:
13C(6) (K and R). The criteria for accepting MS/MS spectra were
Mascot scores above 60 and a false discovery rate (based on peptide
scores) below 2%: The significance threshold was manually lowered
for each MS-analysis to ensure a false discovery rate below 2%, but
was never increased above p .05 (standard setting). Moreover, only
peptides with the highest rank (“red” peptides), i.e. the best match for
the given mass, were used for quantification. The false discovery rate
data were assessed against a human MSIPI decoy database essen-
tially as described previously (25) and calculated as follows: false
discovery rate (%) decoy hits 100/(MSIPI hits decoy hits). Peak
list files were recalibrated using the in-house developed Perl script
MSRecal, and relative quantification of stable isotope-labeled pep-
tides was performed using MSQuant v1.5 (26). MSQuant uses
eXtracted Ion Chromatogram (XIC) for quantification, and all peptides
fulfilling the criteria mentioned above for MS/MS spectra were quan-
tified; no outlier points were removed. The quantifications were nor-
malized to their collective median and imported via a comma sepa-
rated values (CSV) format to ProteinCenter v2.8.1 (Proxeon A/S,
Odense, Denmark) to identify differentially expressed proteins. All
protein identifications from the same biological samples were merged
(36 LC-MS/MS analyses were merged into six biological samples).
The six biological samples were compared, and proteins that were
98% or more similar were clustered into groups to reduce redun-
dancy. The inclusion criteria for the differentially expressed proteins
included in Table I were: identification and quantification in two or
more biological samples by two or more different peptides and dif-
ferential expression above 1.5-fold, which was determined based on
the 5 and 95% percentiles and manual inspection of protein spectra
of proteins known to be associated with cancer. Quantitative and
qualitative data of the differentially expressed proteins were manually
inspected using the Mascot search and MSQuant to verify correct
identification and quantification. Differences in protein expression
were analyzed using the Student’s t test to determine whether the
mean quantification value differed from onefold (no differential ex-
pression). Low p values were preferred when selecting proteins for
inclusion in the biochemical and transcriptional analyses described
below. Further, since only one protein matching each set of peptides
was quantified by MSQuant, the Mascot search results were manually
inspected to identify any isoforms matching the same set of peptides
of the reported differentially expressed proteins in Table I, and no
such isoforms were identified for any of the proteins listed. Previously,
we analyzed the membrane proteins of this cell line model (14, 15),
focusing on the differentially expressed plasma membrane proteins.
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Membrane proteins that exhibited altered expression, but were not
plasma membrane proteins, were included in this study.
Western Blotting—Based on protein concentration measurements,
equal amounts of homogenates from M-4A4 and NM-2C5 cells iso-
lated as described in the protein fractionation section were resolved
on 4–20% SDS-PAGE (Pierce) and electroblotted onto a PVDF mem-
brane. The membranes were blocked in PBS, 0.1% Tween-20, and
5% nonfat dry milk powder for 1 h at room temperature, incubated
with primary antibody anti-CYB5R3 (1:5000, HPA001566, Atlas Anti-
bodies), anti-NPC1 (1:1.000, H00004864-M02, Abnova, Taipei, Tai-
wan), anti-Na/K ATPase (1:20.000, ab7671, Abcam, Cambridge,
UK), or anti--actin (1:20.000, ab6276, Abcam) in PBS, 0.1% Tween-
20, and 5% nonfat dry milk powder) for 1 h at room temperature,
followed by washing (in PBS, 0.1% Tween-20, and 1% nonfat dry milk
powder) and incubation with goat anti-mouse or anti-rabbit HRP-
conjugated secondary antibody (Dako, in PBS, 0.1% Tween-20, and
1% nonfat dry milk powder) for 1 h at room temperature. The mem-
branes were washed in PBS, 0.1% Tween-20 prior to visualization of
immunoreactive bands using ECL Western blot kit or ECL Prime
Western blot kit (Amersham Biosciences).
Quantitative Real-Time PCR—Relative quantification of gene ex-
pression was performed in triplicate using SYBR Green PCR Master
Mix (Applied Biosystems, Foster City, CA) in accordance with the
recommendation of the supplier using a 7500 or a StepOne Real-Time
PCR system (Applied Biosystems). The median relative expression
levels were normalized using the reference genes Thymine-Adenine-
Thymine-Adenine (TATA) box-binding protein, -actin, and Na-K-
ATPase or Na-K-ATPase alone. The primers for specific amplifica-
tion were all obtained from QuantiTect Primer Assay collection
(Qiagen): TBP/TATA box-binding protein, QT00000721; ACTB/-ac-
tin, QT00095431; ATP1A1/Na-K-ATPase, QT00059962; NPC1/
Niemann-pick c1 protein, QT00066465; DDX21/nucleolar RNA he-
licase 2, QT00047187; CYB5R3, QT00090909; and LDHA/L-lactate
dehydrogenase A, QT00001687.
Patient Samples—Formalin-fixed and paraffin-embedded archival
tissue blocks from two cohorts of Danish patients with resectable,
histologically verified, primary invasive breast carcinomas undergoing
surgery at Odense University Hospital were used for this study. The
carcinomas were classified according to the criteria of WHO and
graded according to Bloom and Richardson’s histological grading
system (27). Clinicopathological parameters, including patient age at
diagnosis, tumor size, lymph node status, tumor recurrence, and
follow-up status, were retrospectively obtained from Danish Breast
Cancer Group (DBCG). Observations of follow-up were censored at
ten years after surgery. Disease-free survival (DFS) is defined as
recurrence or death according to Punt et al. (28). Cohort 1 included
women diagnosed with breast cancer from 1990 to 1998. A total of 30
patients were identified retrospectively according to recurrence sta-
tus (50% with recurrence within ten years follow-up), estrogen recep-
tor (ER), progesterone receptor (PR), and HER2 status. The selection
of breast cancer biopsies for cohort 1, the generation of all tissue and
cancer cell line microarrays, and the staining procedures are de-
scribed elsewhere (15). Cohort 2 was also retrospectively identified
and consisted of 122 patients who had undergone surgery between
1997 and 2001 at Odense University Hospital and were registered as
ER-negative (ERneg). Further, a ten year follow-up was required for
those patients who did not develop metastasis from time of surgery to
date of data-withdrawal. Re-evaluation of ER and PR status with
up-to-date immunohistochemical screening classified a number of
patients as ER-positive (ERpos) and/or PRpos: ERneg/PRneg (1% pos-
itive cells, n  101), ERneg/PRneg and HER2 unamplified (triple-neg-
ative, n 74), ERneg/PRneg and HER2 amplified (n 24), ERpos and/or
PRpos, HER2 unamplified (n  19), and ERpos and/or PRpos, HER2
amplified (n  2). Clinical data were retrieved from the Danish Breast
Cancer Cooperative Group (DBCG) database on September 1, 2011.
The majority of patients were enrolled in the DBCG 89, 99 programs
(www.dbcg.dk). Patients had documented local or distant relapses,
death (any cause), or were diagnosed with secondary malignant
disease. Patients received adjuvant chemotherapy according to na-
tional guidelines. Normal liver tissues were also included in the tissue
array (n  1, in quadruplicates) for staining intensity control. For the
tissue arrays, a representative area of each tumor was selected from
a hematoxylin- and eosinstained tumor slide, and 2 mm diameter
cores were retrieved from the corresponding formalin-fixed and par-
affin-embedded tumor block. Each tissue array contained 15–20
cores in duplicate or quadruplicate. The two cohorts were used to
study the association between expression of selected proteins and
metastasis in ERneg patients. Further, anti-CYB5R3 antibodies were
tested on whole-tissue breast tumor specimens to demonstrate ho-
mogenous staining prior to validation of cores on tissue arrays. The
studies were approved by the Regional Scientific Ethical Committee
of Southern Denmark.
Fisher’s exact and Chi-square tests were used to investigate the
significance of the relationship between CYB5R3 and the individual
variables. Hazard ratio (HR) and p values were calculated via Cox
proportional hazard regression model (STATA IC 11 statistical soft-
ware) and DFS demonstrated with Kaplan–Meier plots (GraphPad
Prism statistical software). Uni and multivariate analysis were per-
formed using Cox proportional hazard regression model (STATA IC
11). Only variables with significant p values from univariate analyses
were entered into the multivariate analysis (backward stepwise, prob-
ability for stepwise entry, and removal were set at 0.10 and 0.05). The
p values  .05 denote statistical significance.
Immunocytochemistry and Histochemistry— Tissue array sections
(4 m) from the formalin-fixed and paraffin-embedded tissue or cell
lines were cut, deparaffinized, and rehydrated prior to antigen re-
trieval performed by microwave boiling in Tris EGTA (T-EG) buffer (10
mM Tris and 0.5 mM EGTA, pH 9). Sections were incubated with
anti-ER ab clone 6F11 (Leica Biosystems), HER2 with HerceptestTM
kit (DAKO); anti-NPC1 (1:1.000, HPA026618, Atlas Antibodies, Stock-
holm, Sweden); anti-NRH2 (1:1.000, ab84394, Abcam); anti-CYB5R3
(1:3–6.000, HPA001566, Atlas Antibodies); or anti-LDHA (1:2–4.000,
TA301302, Origene, Rockville, MD) for 1 h at room temperature.
Primary antibody binding was detected with either horseradish per-
oxidase (HRP)-conjugated EnVision™ polymer (K4001, Dako), or
PowerVision Poly-HRP (Novocastra; Leica Biosystems) with 3,3-
diaminobenzidine (K3468, Dako) as chromogen. Microscopy of tis-
sues was performed on a Leica DMLB microscope (100/numerical
aperture [NA] 1.25; Leica Microsystems) using LasV3.6 acquisition
software. Evaluations of the immunohistochemical stainings were
performed by a highly experienced pathologist using bright field
microscopy in a blinded setup. No software-based approach was
used. Based on standard histopathological criteria, the immunohis-
tochemical staining results were rated according to staining intensity:
no, weak, moderate, and strong staining. For cohort 1, a cut-off was
calculated and used to stratify the cancers in two groups, strongly
and weakly stained, using the average value as cut-off between them.
This cut-off was also used for cohort 2.
siRNA Knock-Down—A total of 1–1.5  106 cells were resus-
pended in 100 l Ingenio Electroporation Solution (Mirusbio, Kem-
En-Tec Nordic, Denmark) and siRNA (CYB5R3, GS1727; SI00008743
(CYB5R3 siRNA 1) and SI026663976 (CYB5R3 siRNA 2) Qiagen or
negative control siRNA, SIC001, Sigma-Aldrich) were added to a final
concentration of 0.3 M. The resuspended cells were transfected
using a Nucleofector II (P20 and T20 program, Amaxa, Ko¨ln, Ger-
many). After transfection, the cells were transferred to complete me-
dium, and mRNA levels were determined on day 1–6, 8, 11, and 15;
protein levels on day 2, 3, 4, 6, 8, 11, and 15; proliferation assay on
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day 6, apoptosis assay on day 6; and protein array and experimental
metastasis assay on day 3.
Evaluation of Metastasis Formation In Vivo
The M-4A4 cell line was transfected with luciferase 2 (Luc2)-ex-
pressing lentiviral particles (AMS Biotechnology) using a multiplicity of
infection virus particle concentration of five in complete medium
containing 5 g/ml polybrene (Sigma-Aldrich). The virus-containing
media was replenished with complete medium after 16 h. Stably
luciferase-expressing M-4A4 cells (M-4A4-Luc2) were generated after
blasticidine S (Life Technologies) selection (6 mg/ml) for 5 days. To
ensure that the siRNA knock-down did not influence the biolumines-
cence properties of the cells, the luciferase activity was evaluated on
day 3 after transfection using CYB5R3-targeting siRNAs as well as
control siRNA. No difference in luciferase activity was observed be-
tween the cells transfected with the different siRNAs or untransfected
cells. Further, we performed a Blast search of the siRNAs sequences
on the luciferase gene and found only minimal overlap. Three days
after siRNA transfection, the cells were harvested, resuspended in
PBS at a concentration of 5 106/ml, and 0.2 ml was injected into the
tail vein of 8-week-old female CB-17 SCID mice. All animal experi-
ments were approved by The Experimental Animal Committee, The
Danish Ministry of Justice and performed at the animal facility core at
University of Southern Denmark. The mice were housed under spe-
cific pathogen-free conditions with ad libitum food and drinking wa-
ter. The mice were euthanized if they showed any adverse signs or
symptoms of disease, including weight loss, paralysis, or general
discomfort. Relative quantification of metastasis burden was per-
formed at days 4 and 12 using whole-body bioluminescent imaging
(IVIS-spectrum, Caliper Life Science). Mice were injected with 150 mg
D-luciferin/kg body weight and then anesthetized with isoflurane gas.
Images were acquired starting 10 min after luciferin injection. Regions
of interest were drawn encircling the lung region to quantify meta-
static burden as measured by the relative photon emission (photons/
s/cm2/sr) using Caliper Life Science Living image (version 4.2).
Metastasis development was calculated as the fold increase of
metastatic burden between days 4 and 12. The statistical significance
of metastasis development between two groups was calculated using
the Mann–Whitney statistical test. p values 	 .05 were considered
insignificant. The increase was further analyzed using Grubb’s test for
detecting and removing outliers from the dataset. Before testing for
significant outliers, all values were transformed to their logarithms to
ensure that the data were sampled from a Gaussian distribution.
Protein Array—Three days after transfection, cell lysates (2  106)
were prepared for the Signaling Explorer protein array (Full Moon
Biosystems, Sunnyvale, CA) according to the manufacturer’s proto-
col. Briefly, the cells were washed in PBS containing protease inhib-
itors and harvested by scraping. The washed cells were lysed in
extraction buffer, and the supernatant was cleared by centrifugation
(10.000  g, 20 min). Using a spin column, the extraction buffer was
exchanged with labeling buffer and the protein content was measured
at A280 (Nanodrop ND-1000, Fisher Scientific). CYB5R3 knock-down
was verified by Western blotting prior to biotinylation. A milk-contain-
ing blocking solution was used prior to incubating the protein lysate
(180 g) on array slides, and the slides were washed extensively after
both blocking and protein lysate incubation. Finally, bound biotinyl-
ated proteins were detected using Cy3-streptavidin (Invitrogen). The
slides were scanned and the resulting data were analyzed by Full
Moon Biosystems. The assay was performed in biological duplicates.
Global Pathway Analysis—Global pathway analysis was performed
using the core analysis module of the Ingenuity Pathway Analysis
software (Ingenuity Systems, Inc.). Canonical pathway functions are
based on well-characterized metabolic and cell signaling pathways
that have been curated and hand-drawn by PhD-level scientists,
whereas the network function generates networks based on the data
input and may contain proteins of several pathways.
Apoptosis Assay—An ELISA-based cell death Kit (Roche) was used
to identify differences in apoptosis rate between CYB5R3 siRNA- and
control siRNA-transfected M-4A4 cells. Cells were transfected and
seeded in triplicate in 96-well plates at different densities (2,000–
10,000 cells/well), and the apoptosis rate was measured on day 6 in
accordance with the manufacturer’s instructions. Briefly, cell growth
medium was removed and the cells were lysed in lysis buffer. An
aliquot of the lysate was transferred to a streptavidin-coated plate,
and the immunoreagent (combination anti-histone-biotin-tagged and
anti-DNA binding horse radish peroxidase-conjugated antibodies)
was added. The wells were washed thoroughly after incubation, and
the degree of apoptosis was measured at 405 nm (reference 490 nm)
upon addition of a color-changing peroxidase substrate solution. To
compensate for any cell loss during transfection and any minor dif-
ferences in proliferation, the data were normalized to the number of
cells present using proliferation assay. This assay was performed in
biological triplicates.
Proliferation Assay—Cells (4  104 CYB5R3 siRNA and control
siRNA transfected) were seeded in quadruplicate and stained with
crystal violet on day 6 as described by Lundholt et al. (29). Briefly, the
cells were washed in PBS, followed by incubation (10 min) in 5%
crystal violet (Sigma-Aldrich) and 25% methanol. The crystal violet
was removed, and the cells were washed three times in water and
dried. The crystal violet contained in the dry cells was dissolved in 0.1
M sodium citrate, 50% ethanol, and absorbance measured in triplicate
at 570 nm using a Sunrise microplate Reader (Tecan Trading AG,
Switzerland). This assay was performed in biological quadruplicates.
RESULTS
To identify proteins, particularly intracellular proteins, that
may influence the ability of cancer cells to extravasate, colo-
nize, and establish metastasis at distant sites, we used a
model system consisting of two isogenic human cancer cell
lines (M-4A4 and NM-2C5) that are equally tumorigenic in
immunodeficient mice, but only one forms metastases,
M-4A4, while NM-2C5-derived primary tumors disseminate
single cells to the lungs that remain dormant. Comparison of
protein expression levels in cytosol, mitochondria, and nuclei
fractions of the two cell lines using stable isotopic labeling by
amino acids in cell culture and LC-MS/MS proteomic analysis
in biological and technical triplicates identified a total of 341
proteins, all identified by  2 peptides. Seven proteins exhib-
ited 1.6–6.5-fold altered expression between the two cell
lines and may be potential markers of the ability of cancer
cells to colonize and establish metastasis (Table I). Of these,
CYB5R3, LDHA, NPC1, filamin-A, and NDRG1 exhibited
higher expression in M-4A4 versus NM-2C5, while NRH2 and
synaptic vesicle membrane protein VAT-1 homolog (VAT-1)
exhibited lower expression levels in M-4A4 versus NM-2C5.
Supplemental Data 1 provides the accession number, number
of unique peptides, and list of the sequences for each protein
identified. Supplemental Data 2 provides the identified se-
quence, the precursor m/z, charge, and the Mascot score of
all single peptide-based proteins. The mean and standard
deviation for all quantified proteins and the number of pep-
tides used for quantification are provided in Supplemental
Data 3.
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Biochemical and Transcriptional Evaluation of Proteins Ex-
hibiting Altered Expression—To further evaluate the quantita-
tive proteomic differences observed by mass spectrometry,
the expression levels of four selected proteins were examined
in the two cell lines by immunocytochemistry and/or Western
blotting, and the corresponding gene expression levels were
measured by quantitative real-time PCR.
Immunocytochemical analysis of the NM-2C5 and M-4A4
cell lines, as well as the parental cell line MDA-MB-435, was
performed using a panel of commercial antibodies (Fig. 1).
CYB5R3, LDHA, and NPC1 all showed more intense intracel-
lular staining in M-4A4 and MDA-MB-435 than in NM-2C5, in
accordance with the higher expression seen in the proteome
analysis. LDHA showed homogeneous staining within the cell,
corresponding to a cytosolic distribution, in agreement with
the proteomic analysis that primarily identified this protein in
the cytosolic fractions, whereas CYB5R3 and NPC1 showed
more distinct staining, in agreement with the expected local-
ization in the outer mitochondrial membrane and the endoly-
sosomal organelles, respectively. CYB5R3 and NPC1 were
identified primarily in the mitochondrial fractions, while a low
level of CYB5R3 was also observed in nuclear fractions in the
proteome analysis. Interestingly, analysis of NRH2 showed
distinctly different cellular localizations in NM-2C5 versus
M-4A4 cells: While NRH2 was found in the nucleoplasm in
NM-2C5, it was found in the nucleoli in M-4A4 cells. In MDA-
MB-435 cells, NRH2 was localized in the nucleoli of most
cells, although nucleoplasmic staining was also observed.
NRH2 was identified primarily in the nuclear fractions in the
proteome analysis.
Semi-quantitative measurement of the denatured proteins
by Western blotting was performed using Na/K-ATPase or
-actin for normalization; both proteins were present in quan-
titatively equal amounts in both cell lines based on the pro-
FIG. 1. Comparison of the expression patterns of selected can-
didate proteins in NM-2C5, M-4A4, and MDA-MB-435 cells as
analyzed by immunocytochemistry. Formalin-fixed and paraffin-
embedded cells were stained with antibodies directed against L-lac-
tate dehydrogenase A (LDHA), NADH-cytochrome b5 reductase 3
(CYB5R3), Niemann-pick c1 protein (NPC1), and nucleolar RNA heli-
case 2 (NRH2).
FIG. 2. Investigation of selected intracellular proteins exhibiting
altered expression using Western blotting and quantitative real-
time PCR. (A) Comparison of expression levels of Niemann-pick c1
protein (NPC1) and NADH-cytochrome b5 reductase 3 (CYB5R3) in
NM-2C5 (NM) versus M-4A4 (M) cells measured by Western blotting.
Na/K-ATPase (NKA) and -actin were used as loading controls,
respectively. (B) Comparison of fold-change in expression levels of
mRNA of L-lactate dehydrogenase A (LDHA), CYB5R3, NPC1, and
nucleolar RNA helicase 2 (NRH2) in M-4A4/NM-2C5 cells as meas-
ured by quantitative real-time PCR.
TABLE I
Comparative, quantitative proteomics of proteins showing altered expression levels in M-4A4 vs. NM-2C5






Filamin-A P21333 FLNA 2 4 2.4% 1.1 to 1.8 .07
L-lactate dehydrogenase A P00338 LDHA 6 8 24% 1.2 to 2.5 .01
NADH-cytochrome b5 reductase 3 P00387 CYB5R3 3 4 18% 1.2 to 3.2 .03
Niemann-pick c1 protein O15118 NPC1 2 4 6.3% 5.4 to 6.5 .03
Protein ndrg1 Q92597 NDRG1 2 2 8.8% 1.9 to 2.3 .07
Nucleolar RNA helicase 2 Q9NR30 DDX21 2 4 8.3% –1.2 to –1.6 .08
Synaptic vesicle membrane protein
VAT-1 homolog
Q99536 VAT1 2 2 6.6% –1.3 to –1.6 .13
Uniprot: accession numbers from Uniprot. Samples: the number of samples the proteins were quantified in. Peptides: the maximum number
of peptides identified.
a Fold change in M-4A4 vs. NM-2C5 in biological replicates.
b Student’s t-test.
c Fold change in NM-2C5 vs. M-4A4.
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teomic analysis (Fig. 2A). More intense bands corresponding
to CYB5R3 (estimated molecular weight: 34 kDa) and glyco-
sylated NPC1 (estimated molecular weight: 140 kDa) were, as
expected, observed for M-4A4 compared with NM-2C5 cell
lysate. Further evaluation of mRNA expression levels of the
altered proteins LDHA, CYB5R3, NPC1, and NRH2 using
quantitative real-time PCR also showed altered expression at
the transcriptional level (Fig. 2B).
High Expression of CYB5R3 Correlates with Poor Outcome of
Patients with ERneg Breast Cancer—We next examined the
expression of LDHA, CYB5R3, NPC1, and NRH2 in primary
breast cancer tissue biopsies of two cohorts of patients by
immunohistochemistry (Fig. 3). Cohort 1, consisting of 30 breast
cancer patients who had or had not developed distant metas-
tasis within a ten-year period following surgical removal of the
primary tumor, was evaluated using staining intensity to group
tumors as strongly and weakly stained using the average value
as cut-off between them. The expression of ER, PR, and HER2
was used to further categorize these tumors into the three
breast cancer subtypes: ERpos/PR pos, HER2 amplified, and
triple-negative (ERneg/PRneg/HER2 unamplified). The NM-2C5
and M-4A4 cell lines have previously been shown to be ERneg/
PRneg, and HER2 was unamplified (data not shown), indicating
that these cell lines belong to the triple-negative subtype.
High CYB5R3 expression was more frequently observed in
primary tumors of patients that developed metastasis (67%,
14/21) compared with those that had not (44%, 4/9), although
this did not reach significance (Table II). Strong staining of
NRH2 was also associated with the ERneg/PRneg phenotype
(p  .05) but not correlated with metastasis status, while no
significant correlations between metastasis, recurrence,
ER/PR status, HER2 status, and NPC1 or LDHA staining was
observed. LDHA exhibited heterogeneous staining within the
tumors, with the most intense staining observed in vital tumor
cells adjacent to necrotic areas (Fig. 3).
The expression level of the four candidate proteins was
next examined in primary tumors of a second independent
cohort of 122 breast cancer patients consisting of predomi-
nantly of ERneg/PRneg tumors (n  101) using the cut-off
established with cohort 1. The tumors were grouped accord-
ing to their ER, PR, and HER2 status, and expression of the
four candidate proteins analyzed for the individual subgroups
for correlation to disease-free survival (DFS) and overall sur-
vival (OS)(Table III). The numbers of patients with metastasis
among each breast cancer subtype are listed in Supplemental
Data 4. Cox regression analysis identified two proteins,
CYB5R3 and NRH2, significantly associated with DFS in the
entire cohort (n  122, p  .04 and p  .03, respectively).
High expression levels of CYB5R3 also significantly correlated
with poor outcome in the 101 patients with ERneg tumors
FIG. 3. Staining pattern of antibodies against CYB5R3, NRH2,
NPC1, and LDHA in human breast cancer tissue determined by
immunohistochemical analysis. (A) Antibodies against CYB5R3 and
(B) NPC1 exhibited cytoplasmic staining with perinuclear intensifica-
tion, while (C) NRH2 staining was predominantly observed in nucleoli
with weaker staining in the remaining parts of the nucleus. (D) LDHA
exhibited heterogeneous cytosolic staining within the tumors with the
most intense staining observed in vital tumor cells adjacent to ne-
crotic areas.
TABLE II
Immunohistochemical analysis of protein expression of four candidate proteins in cohort 1 consisting of 30 primary breast cancer biopsies
stratified according to metastasis, recurrence, and receptor status (ER, PR, and HER2). Distant metastasis and recurrence were registered
within a 10-year period
LDHA CYB5R3 NPC1 NRH2
Node-positive and/or distant metastasis 45 (9/20)a 67 (14/21) 53 (10/19) 42 (8/19)
Node-negative and no metastasis 67 (6/9) 44 (4/9) 44 (4/9) 44 (4/9)
Recurrence 40 (6/15) 67 (10/15) 54 (7/13) 50 (7/14
No Recurrence 64 (9/14) 53 (8/15) 47 (7/15) 36 (5/14)
ERneg/PRneg/HER2unamplified 50 (4/8) 67 (6/9) 63 (5/8) 57 (4/7)
ERpos/PRpos and/or HER2amplified 52 (11/21) 57 (12/21) 45 (9/20) 38 (8/21)
ERpos and/or PRpos 56 (10/18) 50 (9/18) 47 (8/17) 28 (5/18)b
ERneg/PRneg 46 (5/11) 75 (9/12) 55 (6/11) 70 (7/10)b
HER2 amplified 50 (4/8) 75 (6/8) 29 (2/7) 38 (3/8)
HER2 unamplified 52 (11/21) 55 (12/22) 57 (12/21) 45 (9/20)
a 9/20 indicates strong staining in nine of 20 biopsies.
b p 0.05 (Fisher’s exact test), LDHA—L-lactate dehydrogenase A, CYB5R3—NADH-cytochrome b5 reductase 3, NPC1—Niemann-pick c1
protein, NRH2—nucleolar RNA helicase 2, ER—estrogen receptor, PR—progesterone receptor, HER2—receptor tyrosine-protein kinase
erbB-2, amp—amplification, neg—negative, pos—positive.
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(DFS, p  .02; HR  1.87, 95% CI of ratio: 1.1–3.19; median
DFS: 1178 days versus 	3,650 days, Fig. 4A and OS p  .04;
HR  1.73, 95% CI of ratio: 1.02–2.94; median OS: 2,238
days versus	3,650 days)(Fig. 4B) but not in the smaller ERpos
group. NRH2 was also significantly associated with DFS in the
small ERpos group (n  21, DSF and OS p  .04, HR  10.3,
95% CI of ratio 1.15–92.9; median DFS: 2,737 days versus
	3,650 days) but not in the ERneg group.
The clinicopathologic characteristics at the time of surgery
according to CYB5R3weak and CYB5R3strong staining in the
ERneg/PRneg, ERneg/PRneg/HER2unamplified (triple-negative),
ERneg/PRneg/HER2amplified, and ERpos and/or PRpos groups,
respectively, identified no differences relative to age, tumor
size, nodal status, and tumor grade (chi-square test, Supple-
mental Data 5). Univariate and multivariate Cox proportional
hazard regression analyses were performed to identify the
independent prognostic value of each variable for DFS and
OS. CYB5R3 expression and clinicopathological characteris-
tics, including age, tumor size, tumor grade, and lymph node
status, were included in the multivariate analysis (Table IV).
CYB5R3 and lymph node status were identified as independ-
ent prognostic factors of DFS and OS in ERneg breast cancer
patients (HR: 1.93, 95% CI: 1.12–3.31, p  .02, and HR: 1.78,
95% CI: 1.04–3.07, p  .04, respectively, Table IV). The
results from the multivariate analysis revealed a 1.9-fold
higher risk of poor outcome for ERneg tumor patients exhibit-
ing strong versus weak staining of CYB5R3.
High Expression of CYB5R3 Correlates with Metastatic Ca-
pabilities of Triple-Negative Cell Lines in Mice—The expres-
sion of CYB5R3 in a total of nine triple-negative breast cancer
cell lines showed a correlation between strong expression of
CYB5R3 and metastatic capability in mice (Table V). Four cell
lines known to metastasize in mice had strong staining, while
three cell lines known to lack metastatic capabilities had low
expression of CYB5R3. For two cell lines, the metastatic
capabilities were unknown.
Reduction of CYB5R3 Expression by Knock-Down in
M-4A4 Cells Inhibit the Late Steps in the Metastatic Process In
Vivo—To investigate the role of CYB5R3 in the late steps of
the metastatic process (extravasation and/or colonization),
the gene was knocked-down in M-4A4 cells using transient
transfection with two different siRNAs (CYB5R3 siRNA 1 and
2, respectively), which resulted in 	90% reduction in the
mRNA level of CYB5R3 in M-4A4 cells (Supplemental Fig. 1A)
and corresponding decrease in CYB5R3 protein expression
as evaluated by Western blotting (Supplemental Fig. 1B).
CYB5R3 expression was decreased from days 2 to 11 for
CYB5R3 siRNA 1 and day 2 to 6 for CYB5R3 siRNA2, with the
level being lowest on days 2–6.
The effect of CYB5R3 on lung metastasis burden was eval-
uated by injecting 106 M-4A4 cells transfected with CYB5R3
siRNA 1 or control siRNA into the tail vein of immunodeficient
mice (n  10 in each group) and monitoring them by biolumi-
nescence imaging (days 4 and 12). Metastasis burden was
calculated as the fold increase of lung metastases at day 12
as measured by quantitative bioluminescence using the
measurement at day 4 for comparison and was shown to be
significantly lower in mice injected with CYB5R3 siRNA-trans-
TABLE III
Immunohistochemical analysis of protein expression of four candidate proteins in cohort 2 consisting of 122 primary breast cancer biopsies
stratified according to receptor status (ER, PR, and HER2). Disease-free survival (DFS) and overall survival (OS) with a 10-year follow-up period
was evaluated using Cox regression analysis
LDHA CYB5R3 NPC1 NRH2
p- value HR (95% CI) a p- value HR (95% CI) p- value HR (95% CI) p- value HR (95% CI)
All tumors DFS .58 0.86 .04b 1.72 .49 0.84 .03b 1.76
(n  122) (0.51–1.46) (1.04–2.87) (0.50–1.39) (1.04–2.96)
OS .6 0.87 .06 1.62 .66 0.89 .03b 1.8
(0.51–1.48) (0.98–2.69) (0.54–1.49) (1.07–3.02)
ERneg and PRneg DFS .58 0.86 .02b 1.87 .67 0.89 .3 1.33
(n  101) (0.49–1.49) (1.1–3.19) (0.52–1.52) (0.78–2.29)
OS .62 0.87 .04b 1.73 .9 0.96 .25 1.37
(0.5–1.5) (1.02–2.94) (0.56–1.64) (0.8–2.36)
ERneg/PRneg/HER2unamp DFS .23 0.66 .09 1.75 .86 0.94 .67 1.15
(n  74) (0.34–1.3) (0.92–3.32) (0.5–1.78) (0.60–2.21)
OS .23 0.66 .13 1.65 .96 1.02 .69 1.14
(0.34–1.3) (0.87–3.12) (0.54–1.92) (0.6–2.19)
ERpos and/or PRpos DFS .5 0.47 .58 0.54 .87 0.87 .04b 10.3
(n  21) (0.05–4.2) (0.06–4.81) (0.14–5.19) (1.15–92.9)
OS .5 0.47 .58 0.54 .87 0.87 .04b 10.3
(0.05–4.2) (0.06–4.81) (0.14–5.19) (1.15–92.9)
HER2 amp DFS .38 1.6 .1 2.43 .86 0.91 .25 1.84
(n  24) (0.56–4.59) (0.85–6.93) .91 (0.32–2.63) .14 (0.66–5.13)
OS .3 1.75 .18 2.04 1.06 2.17
(0.61–5.01) (0.72–5.77) (0.37–3.08) (0.78–6.01)
a Hazard ratio (95% confidence interval).
b p  .05 (Cox regression analysis). LDHA—L-lactate dehydrogenase A, CYB5R3—NADH-cytochrome b5 reductase 3, NPC1—Niemann-
pick c1 protein, NRH2—nucleolar RNA helicase 2, ER—estrogen receptor, PR—progesterone eceptor, HER2—receptor tyrosine-protein
kinase erbB-2, amp—amplified, unamp—unamplified, neg—negative, pos—positive.
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fected M-4A4 cells than in those injected with control siRNA-
transfected M-4A4 cells (p  .05, Fig. 5), indicating that
knock-down of CYB5R3 in M-4A4 cells inhibits their extrava-
sation and/or colonization.
CYB5R3 Gene Knock-Down in M-4A4 Cells Influence Sig-
naling Associated with Extravasation, Apoptosis and TGF-
and HIF-Pathways—To investigate the consequences of the
gene knock-down on cell signaling, protein lysates from
M-4A4 cells at day 3 following CYB5R3 siRNA 1 or control
siRNA transfection were analyzed for alterations in 1,360 sig-
naling molecules using antibody array (Supplemental Data 6).
FIG. 4. NADH-cytochrome b5 reductase 3 (CYB5R3) protein expression correlates with disease-free survival (DFS) and overall
survival (OS) of patients with estrogen receptor-negative (ERneg) breast cancer (p< .02 and .04, respectively, Cox regression analysis).
Kaplan–Meier curves illustrate (A) DSF and (B) OS of ERneg breast cancer patients of cohort 2.
TABLE IV
Univariate and multivariate analysis of CYB5R3 expression in ERneg
breast cancer patients of cohort 2
Univariate Multivariate
Variable p value HR (95% CI) p value HR (95% CI)
Age
DFS .41 1.27 (0.72–2.25)
OS .62 1.39 (0.78–2.46)
Tumor size
DFS .90 1.07 (0.38–2.96)
OS .97 1.02 (0.37–2.83)
Lymph node status
DFS .11 1.59 (0.9–2.81) .05a 1.74 (1.01–3.02)
OS .09 1.63 (0.92–2.88) .04a 1.77 (1.02–3.07)
Tumor grade
DFS .43 1.31 (0.68–2.52)
OS .36 1.35 (0.71–2.57)
CYB5R3
DFS .02a 1.87 (1.1–3.19) .02a 1.93 (1.12–3.31)
OS .04 1.73 (1.02–2.94) .04a 1.78 (1.04–3.07)
p values were calculated by cox regression analysis.
a p  .05 is considered significant. CYB5R3—NADH-cytochrome
b5 reductase 3.
TABLE V
Immunocytochemical analysis of CYB5R3 expression in triple-nega-
tivea breast cancer cell lines stratified according to their metastatic
capability in mice
Cell line Metastatic capabilityin mice References CYB5R3 expression
MDA-MB-435  (37) 
M-4A4  (8, 9) 
Cal51  (38) 
MDA-MB-231  (39, 40) 
NM-2C5 - (8, 9) /
BT20 - (41) 




CYB5R3—NADH-cytochrome b5 reductase 3.
FIG. 5. Knock-down of NADH-cytochrome b5 reductase 3
(CYB5R3) inhibits metastasis formation of M-4A4 cells after in-
travenous injection. CYB5R3 siRNA 1- or control siRNA-transfected
cells (106) were injected into the tail vein of female CB-17 SCID mice.
(A) Lung metastasis development in mice injected with CYB5R3
siRNA 1- or control (ctr) siRNA-transfected cells (n  10 per group)
was monitored by bioluminescence imaging. (B) Comparison of me-
tastasis development calculated as the fold increase of lung metas-
tases between days 4 and 12. CYB5R3 knock-down significantly
inhibited metastasis development compared with control cells. Me-
tastasis development was compared using the Mann Whitney statis-
tical test (p  .05).
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Of these, 49 showed differential expression (	1.5-fold) be-
tween M-4A4 cells transfected with CYB5R3 siRNA and those
transfected with control siRNA. IPA analysis revealed that
seven of these proteins were involved in decrease of apopto-
sis and cell death signaling (versus 38 proteins in the entire
data set of 1,360 proteins, p  .01, Fishers exact test), in-
cluding mitogen-activated protein kinase (MAPK) 1 (1.6-fold
increase in M-4A4 cells transfected with CYB5R3 siRNA ver-
sus control siRNA), BCL2-associated agonist of cell death
(1.5-fold increase), and caspase 2, 6, and 8 (1.6-, 1.8-, and
1.6-fold decrease, respectively)(Table VI and Supplemental
Fig. 2). Other pathways included extravasation signaling (7 of
49 versus 65 of 1,360, p  .05): Claudin 5, MAPK1, and 11
(1.7-, 1.6-, and 1.5-fold increase, respectively); -catenin, and
matrix metallopeptidase (MMP) 1, 12, and 14 (1.7-, 1.6-, 2-,
and 1.5-fold decrease, respectively); TGF-signaling (5 of 49
versus 25 of 1,360, p  .01): MAPK 1 and 11 and CREB
binding protein, inhibin , and TGF receptor 2 (1.5, 1.8,
and1.8-fold decrease, respectively), and HIF signaling (6 of
49 versus 40 of 1,360, p  .01): MAPK 1 and 11, CREB
binding protein, and MMP 1, 12, and 14.
Biological Validation of the Protein Array Data—To validate
the biological significance of the apoptosis-associated pro-
tein alterations observed by protein array, the effect of
CYB5R3 knock-down on apoptosis was investigated. M-4A4
cells transfected with CYB5R3 siRNA 1, 2, or control siRNA
were examined using an ELISA-based cell death assay, which
showed between 3.6- and 5.4-fold decrease in apoptosis of
the CYB5R3 siRNA versus control siRNA transfected cells at
day 6 following transfection (Fig. 6, p  .01), confirming the
protein array data.
DISCUSSION
The ability of cancer cells to establish metastasis at distant
sites is a complex process that involves interactions between
cancer cells and surrounding tissues as well as cellular sig-
naling within the cancer cells. The precise nature of these
processes is poorly understood and is difficult to study in
clinical samples. We used a cell model system that depicts
the ability of tumor cells to extravasate, colonize, and form
metastases at distant sites, and by quantitative, comparative
proteomics of cytosolic, nuclear, and mitochondrial fractions,
we identified seven intracellular proteins exhibiting signifi-
cantly altered expression, including CYB5R3, which exhibited
higher expression levels in the metastatic versus nonmeta-
static cell lines.
CYB5R3 (NADH-cytochrome b5 reductase 3) is a mem-
brane-bound enzyme found in the plasma membrane, mito-
chondrial outer membrane, endoplasmic reticulum, and other
membranes of most cell types, while a soluble form is present
in red cells (30). CYB5R3 participates in cholesterol biosyn-
thesis, fatty acid homeostasis, and P-450-mediated hydroxyl-
ation of drugs and steroid hormones. Finally, CYB5R3 is
involved in the trans-plasma membrane redox system that
both protects against extracellular oxidants and prevents ini-
tiation of apoptosis by specific mechanisms (30, 31). CYB5R3
is believed to play a role in cellular aging (31), and Siendones
and colleagues (32) showed that CYB5R3 is involved in pro-
tection against cellular senescence as the primary human
fibroblasts aged. However, no studies have yet examined the
role of CYB5R3 in cancer, including metastasis.
The higher expression level of CYB5R3 in M-4A4 versus
NM-2C5 cells, as observed by our proteomic study, was
validated using Western blotting and immunocytochemistry,
and similar expression differences were observed at the tran-
scriptional level. Immunohistochemical analysis of CYB5R3
expression in a large cohort of ERneg/PRneg breast cancer
patients identified a significant correlation between high
CYB5R3 expression and poor DFS and OS. Moreover, multi-
variate analysis revealed a 1.9-fold higher risk of poor out-
come for ERneg/PRneg patients exhibiting strong staining of
CYB5R3 compared with those expressing weak staining. A
correlation between CYB5R3 expression and outcome did not
TABLE VI
Proteins related to apoptosis signaling exhibiting differential expres-
sion in cells transfected with siRNA against CYB5R3 compared to
cells transfected with control siRNA




BAD BCL2-associated agonist of cell
death
1,5
DFFA DNA fragmentation factor,
45kDa, alpha Polypeptide
–1,5
CASP2 Caspase 2, apoptosis-related
cysteine peptidase
–1,6
PARP1 Poly (ADP-ribose) polymerase 1 –1,6
CASP8 Caspase 8, apoptosis-related
cysteine peptidase
–1,7
CASP6 Caspase 6, apoptosis-related
cysteine peptidase
–1,8
CYB5R3—NADH-cytochrome b5 reductase 3.
FIG. 6. Knock-down of NADH-cytochrome b5 reductase 3
(CYB5R3) leads to decreased apoptosis in M-4A4 cells compared
with cells transfected with control siRNA. CYB5R3 expression was
knocked down using two CYB5R3 siRNA and the effect on apoptosis
was measured using an ELISA-based cell death assay. CYB5R3
siRNA 1 versus control (ctr) siRNA exhibited 5.4-fold difference
(p  .01), while CYB5R3 siRNA 2 versus siRNA control exhibited
3.5-fold difference (p  .01).
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reach significance in the ERneg/PRneg/HER2unamplified sub-
group, likely due to the smaller sample size.
The role of CYB5R3 in metastatic M-4A4 cells was investi-
gated by gene knock-down using transient transfection with
two different siRNAs. An experimental metastasis assay
based on injection of CYB5R3 siRNA- and control siRNA-
transfected M-4A4 cells, respectively, into the tail vein of
immunodeficient mice showed that the tumor burden in lungs
was significantly lower in the mice injected with M-4A4 cells
transfected with CYB5R3 siRNA versus control siRNA, indi-
cating that the CYB5R3 knock-down in M-4A4 inhibits extrav-
asation and/or colonization.
To illuminate the effect of CYB5R3 knock-down at the
molecular level, cell lysates from CYB5R3 siRNA- and control
siRNA-transfected M-4A4 cells, respectively, were analyzed
using signaling protein arrays, analysis of which indicated a
role for CYB5R3 in signaling associated with extravasation,
apoptosis, and TGF and HIF pathways. The biological va-
lidity of the protein array data was confirmed by a DNA/
histone ELISA assay showing a 4.5-fold decrease of apopto-
sis in CYB5R3 siRNA-transfected cells compared with control
transfected cells.
It should be noted that there is a continued debate as to
whether the parental cell line of our cell line model, MDA-MB-
435, originated from a breast cancer or a melanoma. MDA-
MB-435 was originally derived from a pleural effusion of a
patient with invasive ductal carcinoma (33), but the breast
cancer origin was questioned when a microarray study
showed that MDA-MB-435 had a gene expression pattern
primarily resembling melanoma cells (34). However, other
studies have shown that MDA-MB-435 expresses breast-
specific markers and can be induced to secrete milk lipids, a
characteristic unique to breast cancer cell lines, thereby con-
firming it is a breast cancer cell line (35). Montel and col-
leagues (36) later showed that surgically excised primary hu-
man breast cancers, as well as other human breast cancer cell
lines, also expressed melanoma-related genes, demonstrat-
ing that this is a common phenomenon of breast carcinomas
and confirming that MDA-MB-435 is of breast cancer origin.
Whether or not MDA-MB-435 is a breast cancer cell line, the
isogenic cell lines comprise a good representative model
system for analyzing differences in cancer extravasation and
colonization.
This study demonstrates the feasibility of mass spectrom-
etry and other proteomics techniques to identify novel key
pathways associated with the ability of cancer cells to colo-
nize and establish metastasis in distant organs. The study
was designed to focus on intracellular proteins, thereby in-
creasing the likelihood of identifying proteins involved in in-
tracellular processes allowing cancer cells to colonize in the
new environment. This study complements our earlier findings
on plasma membrane proteins involved in the same model
(14, 15) and adds to the global picture of protein alteration
associated with distinct steps of the metastatic process.
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